BackgroundCheck.run
Search For

Ling Chen, 405849 Common Cir, Indianapolis, IN 46220

Related to:
Xiaochun Chen 54 Jinsong Chen 45 Wen Qiu Chen 54

Ling Chen Phones & Addresses

Indianapolis, IN   

Abilene, TX   

Philadelphia, PA   

Languages

English
Get Report
Control this profile

Mentions for Ling Chen

Career records & work history

Medicine Doctors

Ling P. Chen

Specialties:
Obstetrics & Gynecology
Work:
Ling P Chen MD
2505 Samaritan Dr STE 107, San Jose, CA 95124
408-3588852 (phone) 408-3588303 (fax)
Education:
Medical School
Case Western Reserve University School of Medicine
Graduated: 1992
Procedures:
Cesarean Section (C-Section), Cystoscopy, D & C Dilation and Curettage, Delivery After Previous Caesarean Section, Hysterectomy, Myomectomy, Oophorectomy, Ovarian Surgery, Tubal Surgery, Vaccine Administration, Vaginal Delivery, Vaginal Repair
Conditions:
Abnormal Vaginal Bleeding, Breast Disorders, Conditions of Pregnancy and Delivery, Endometriosis, Female Infertility, Genital HPV, Premenstrual Syndrome (PMS), Spontaneous Abortion, Uncomplicated or Low Risk Pregnancy and Delivery, Candidiasis of Vulva and Vagina, Complicating Pregnancy or Childbirth, Diabetes Mellitus Complicating Pregnancy or Birth, Ectopic Pregnancy, Hemorrhoids, Herpes Genitalis, Menopausal and Postmenopausal Disorders, Ovarian Dysfunction, Pelvic Inflammatory Disease (PID), Polycystic Ovarian Syndrome (PCOS), Pregnancy-Induced Hypertension, Uterine Leiomyoma
Languages:
Chinese, English
Description:
Dr. Chen graduated from the Case Western Reserve University School of Medicine in 1992. She works in San Jose, CA and specializes in Obstetrics & Gynecology. Dr. Chen is affiliated with El Camino Hospital Of Los Gatos and Good Samaritan Hospital.
Ling Chen Photo 1

Ling Chen, Plymouth Meeting PA - LPN (Licensed practical nurse)

Specialties:
Practical Nursing (Licensed Practical Nurse)
Address:
2250 Hickory Rd, Plymouth Meeting, PA 19462
610-8321122 (Phone)
Languages:
English

Ling L. Chen

Specialties:
Dermatopathology
Work:
Dermatology Associates Of Georgia LLCDermatology Associates Of Georgia
2665 N Decatur Rd STE 650, Decatur, GA 30033
404-5080566 (phone) 404-5080567 (fax)
Site
Education:
Medical School
Lanzhou Med Coll, Lanzhou City, Gansu, China
Graduated: 1982
Languages:
English
Description:
Dr. Chen graduated from the Lanzhou Med Coll, Lanzhou City, Gansu, China in 1982. She works in Decatur, GA and specializes in Dermatopathology.
Ling Chen Photo 2

Ling Ping Chen

Specialties:
Obstetrics & Gynecology
Gynecology
Obstetrics
Education:
Case Western Reserve University(1992)

Publications & IP owners

Us Patents

Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized Hiv1-Gag, Pol, Nef And Modifications

US Patent:
6733993, May 11, 2004
Filed:
Sep 14, 2001
Appl. No.:
09/952060
Inventors:
Emilio A. Emini - Wayne PA
Rima Youil - North Wales PA
Andrew J. Bett - Landsdale PA
Ling Chen - Blue Bell PA
David C. Kaslow - Bryn Mawr PA
John W. Shiver - Doylestown PA
Timothy J. Toner - Marlton NJ
Danilo R. Casimiro - Harleysville PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C12P 2106
US Classification:
435 691, 435 5, 435 71, 435325, 4353391, 53038835, 536 231, 4241991, 4242081
Abstract:
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

Adenovirus Carrying Gag Gene Hiv Vaccine

US Patent:
6787351, Sep 7, 2004
Filed:
Mar 27, 2001
Appl. No.:
09/818443
Inventors:
Ling Chen - Blue Bell PA
John W. Shiver - Doylestown PA
Andrew J. Bett - Lansdale PA
Danilo R. Casimiro - Harleysville PA
Michael J. Caulfield - Fort Washington PA
Michael A. Chastain - Glenside PA
Emilio A. Emini - Strafford PA
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
C12N 1574
US Classification:
4353201, 435 691, 435 692, 424 932
Abstract:
An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

Synthetic Human Papillomavirus Genes

US Patent:
7001995, Feb 21, 2006
Filed:
Aug 21, 2000
Appl. No.:
09/642405
Inventors:
Michael P Neeper - Collegeville PA, US
William L. McClements - Doylestown PA, US
Kathrin U. Jansen - Doylestown PA, US
Loren D. Schultz - Harleysville PA, US
Ling Chen - Blue Bell PA, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07H 21/04
C12N 15/74
A61K 48/00
C12P 21/06
US Classification:
536 231, 4353201, 435 691, 424 9321, 514 44
Abstract:
Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

Synthetic Human Papilloma Virus Genes

US Patent:
7211569, May 1, 2007
Filed:
Dec 4, 2003
Appl. No.:
10/728131
Inventors:
Michael P Neeper - Collegeville PA, US
William L. McClements - Doylestown PA, US
Kathrin U. Jansen - Doylestown PA, US
Loren D. Schultz - Harleysville PA, US
Ling Chen - Blue Bell PA, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 48/00
C07H 21/04
US Classification:
514 44, 435 691, 4353201, 536 231, 424 9321
Abstract:
Synthetic DNA molecules encoding papillomavirus proteins are provided. The codons of the synthetic molecules are codons preferred by the projected host cell. The synthetic molecules may be used as a polynucleotide vaccine which provides effective immunoprophylaxis against papillomavirus infection through stimulation of neutralizing antibody and cell-mediated immunity.

Adenovirus Carrying Gag Gene Hiv Vaccine

US Patent:
2003022, Dec 11, 2003
Filed:
Jun 13, 2003
Appl. No.:
10/461030
Inventors:
Ling Chen - Blue Bell PA, US
John Shiver - Doylestown PA, US
Andrew Bett - Lansdale PA, US
Danilo Casimiro - Harleysville PA, US
Michael Caulfield - Fort Washington PA, US
Michael Chastain - Glenside PA, US
Emilio Emini - Strafford PA, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K039/12
C12N007/00
C12N015/867
C12N015/861
US Classification:
424/199100, 435/456000, 435/235100
Abstract:
An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.

Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized Hiv1-Gag, Pol.nef And Modifications

US Patent:
2004010, May 27, 2004
Filed:
Mar 14, 2003
Appl. No.:
10/380641
Inventors:
Emilio Emini - Wayne PA, US
Rima Youil - North Wales PA, US
Andrew Bett - Lansdale PA, US
Ling Chen - Blue Bell PA, US
David Kaslow - Rancho Santa Fe CA, US
John Shiver - Chalfont PA, US
Timothy Toner - Marlton NJ, US
Danilo Casimiro - Harleysville PA, US
International Classification:
C12Q001/68
C12P021/06
C12N015/00
C12N015/09
C12N015/63
C12N015/70
C12N015/74
US Classification:
435/320100, 435/069100, 435/006000
Abstract:
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV-1 Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized Hiv1-Gag, Pol, Nef And Modifications

US Patent:
2005007, Mar 31, 2005
Filed:
Aug 7, 2003
Appl. No.:
10/636730
Inventors:
Emilio Emini - Wayne PA, US
Rima Youil - North Wales PA, US
Andrew Bett - Lansdale PA, US
Ling Chen - Blue Bell PA, US
David Kaslow - Bryn Mawr PA, US
John Shiver - Doylestown PA, US
Timothy Toner - Marlton NJ, US
Danilo Casimiro - Harleysville PA, US
International Classification:
A61K039/12
C12N007/00
C12N015/861
US Classification:
435456000, 435235100
Abstract:
First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1-Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

Vaccine Using Papilloma Virus E Proteins Delivered By Viral Vector

US Patent:
2005011, Jun 2, 2005
Filed:
Aug 19, 2002
Appl. No.:
10/487148
Inventors:
Lingyi Huang - Norristown PA, US
Kathrin Jansen - Doylestown PA, US
William McClements - Doylestown PA, US
Juanita Monteiro - Cheltenham PA, US
Loren Schultz - Harleysville PA, US
Timothy Tobery - Wilmington DE, US
Ling Chen - The Woodlands TX, US
International Classification:
A61K048/00
C12N015/861
US Classification:
424093200, 514044000, 435456000
Abstract:
Cell-mediated immune response to a infection can be induced by vaccination with DNA encoding E genes. E genes can both prevent the occurrence of disease, and treat disease states. Canine (COPV) E genes which are codon-optimized to enhance expression in host cells are also given.

Possible Relatives

Cynthia Chen  David Chen  Cyril X Chen  Cyrus Y Chen  Dawei W Chen  De T Chen  Dafang Chen  Ling N Le  Ling K Leung  Ling L Li 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.